Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues

Research output: Contribution to journalReview article

80 Citations (Scopus)

Abstract

Although men have a higher risk of atrial fibrillation compared with women, the absolute number of women with atrial fibrillation is greater. Congestive heart failure increases the risk of developing atrial fibrillation in women more than in men, and the prognosis for women with atrial fibrillation is worse than for men. The longer baseline corrected QT interval in women is well known. The mechanism is likely the result of increased circulating androgens, causing the QT interval to shorten in men after puberty. Female sex is associated with an increased risk of torsades de pointes in the setting of potassium antagonists. Class III antiarrhythmic drugs are frequently used for the treatment of atrial fibrillation in heart failure patients because of their neutral effect on mortality and their tolerance by patients with low ejection fractions. Although amiodarone and azimilide carry a low potential for producing torsades de pointes compared with sotalol and dofetilide, the prevalence of torsades de pointes in women is at least twice that in men for all these drugs. Careful monitoring of the QT interval and potassium level, as well as control of congestive heart failure, can help reduce the risk of proarrhythmia. Avoidance of polypharmacy with other potassium antagonists and unmonitored drug formulation changes are important in the management of all patients taking class III agents, but they are particularly crucial in women with additional risk factors for torsades de pointes.

Original languageEnglish (US)
Pages (from-to)39-44
Number of pages6
JournalAmerican Journal of Cardiology
Volume91
Issue number6 SUPPL. 1
DOIs
StatePublished - Mar 20 2003

Fingerprint

Sex Characteristics
Torsades de Pointes
Atrial Fibrillation
Potassium
Heart Failure
Sotalol
Polypharmacy
Drug Compounding
Amiodarone
Anti-Arrhythmia Agents
Puberty
Androgens
Mortality
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{a20b48e252e74fab9f5ded81677b5495,
title = "Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues",
abstract = "Although men have a higher risk of atrial fibrillation compared with women, the absolute number of women with atrial fibrillation is greater. Congestive heart failure increases the risk of developing atrial fibrillation in women more than in men, and the prognosis for women with atrial fibrillation is worse than for men. The longer baseline corrected QT interval in women is well known. The mechanism is likely the result of increased circulating androgens, causing the QT interval to shorten in men after puberty. Female sex is associated with an increased risk of torsades de pointes in the setting of potassium antagonists. Class III antiarrhythmic drugs are frequently used for the treatment of atrial fibrillation in heart failure patients because of their neutral effect on mortality and their tolerance by patients with low ejection fractions. Although amiodarone and azimilide carry a low potential for producing torsades de pointes compared with sotalol and dofetilide, the prevalence of torsades de pointes in women is at least twice that in men for all these drugs. Careful monitoring of the QT interval and potassium level, as well as control of congestive heart failure, can help reduce the risk of proarrhythmia. Avoidance of polypharmacy with other potassium antagonists and unmonitored drug formulation changes are important in the management of all patients taking class III agents, but they are particularly crucial in women with additional risk factors for torsades de pointes.",
author = "Deborah Wolbrette",
year = "2003",
month = "3",
day = "20",
doi = "10.1016/S0002-9149(02)03378-7",
language = "English (US)",
volume = "91",
pages = "39--44",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6 SUPPL. 1",

}

Risk of proarrhythmia with class III antiarrhythmic agents : Sex-based differences and other issues. / Wolbrette, Deborah.

In: American Journal of Cardiology, Vol. 91, No. 6 SUPPL. 1, 20.03.2003, p. 39-44.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Risk of proarrhythmia with class III antiarrhythmic agents

T2 - Sex-based differences and other issues

AU - Wolbrette, Deborah

PY - 2003/3/20

Y1 - 2003/3/20

N2 - Although men have a higher risk of atrial fibrillation compared with women, the absolute number of women with atrial fibrillation is greater. Congestive heart failure increases the risk of developing atrial fibrillation in women more than in men, and the prognosis for women with atrial fibrillation is worse than for men. The longer baseline corrected QT interval in women is well known. The mechanism is likely the result of increased circulating androgens, causing the QT interval to shorten in men after puberty. Female sex is associated with an increased risk of torsades de pointes in the setting of potassium antagonists. Class III antiarrhythmic drugs are frequently used for the treatment of atrial fibrillation in heart failure patients because of their neutral effect on mortality and their tolerance by patients with low ejection fractions. Although amiodarone and azimilide carry a low potential for producing torsades de pointes compared with sotalol and dofetilide, the prevalence of torsades de pointes in women is at least twice that in men for all these drugs. Careful monitoring of the QT interval and potassium level, as well as control of congestive heart failure, can help reduce the risk of proarrhythmia. Avoidance of polypharmacy with other potassium antagonists and unmonitored drug formulation changes are important in the management of all patients taking class III agents, but they are particularly crucial in women with additional risk factors for torsades de pointes.

AB - Although men have a higher risk of atrial fibrillation compared with women, the absolute number of women with atrial fibrillation is greater. Congestive heart failure increases the risk of developing atrial fibrillation in women more than in men, and the prognosis for women with atrial fibrillation is worse than for men. The longer baseline corrected QT interval in women is well known. The mechanism is likely the result of increased circulating androgens, causing the QT interval to shorten in men after puberty. Female sex is associated with an increased risk of torsades de pointes in the setting of potassium antagonists. Class III antiarrhythmic drugs are frequently used for the treatment of atrial fibrillation in heart failure patients because of their neutral effect on mortality and their tolerance by patients with low ejection fractions. Although amiodarone and azimilide carry a low potential for producing torsades de pointes compared with sotalol and dofetilide, the prevalence of torsades de pointes in women is at least twice that in men for all these drugs. Careful monitoring of the QT interval and potassium level, as well as control of congestive heart failure, can help reduce the risk of proarrhythmia. Avoidance of polypharmacy with other potassium antagonists and unmonitored drug formulation changes are important in the management of all patients taking class III agents, but they are particularly crucial in women with additional risk factors for torsades de pointes.

UR - http://www.scopus.com/inward/record.url?scp=0037456807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037456807&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(02)03378-7

DO - 10.1016/S0002-9149(02)03378-7

M3 - Review article

C2 - 12670641

AN - SCOPUS:0037456807

VL - 91

SP - 39

EP - 44

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6 SUPPL. 1

ER -